Target intelligence / Profile preview

Cytotoxic T-lymphocyte (CTL) and Natural killer (NK) cell (CTL/NK cell)

Target
CTL/NK cell
Molecular classification
Other (Immune Cell Type)
01

Overview

Cytotoxic T-lymphocytes (CTLs) and Natural Killer (NK) cells are the primary effector cells of the immune system responsible for the surveillance and elimination of virally infected or neoplastic cells (StatPearls: NK Cells, 2023; StatPearls: Cytotoxic T Cells, 2023). CTLs are CD8+ adaptive immune cells that recognize specific peptide antigens presented on MHC class I molecules, while NK cells are innate lymphocytes that respond to "missing self" or stress-induced ligands (Janeway's Immunobiology, 9th ed.). Both populations execute their cytotoxic function through the directed exocytosis of granules containing perforin and granzymes, which trigger apoptosis in the target cell (Nature Reviews Immunology, 2020). In the context of modern medicine, these cells are not molecular targets themselves but are the functional units modulated by immunotherapies such as checkpoint inhibitors (e.g., Nivolumab) and cytokines (e.g., IL-2) to restore or enhance anti-tumor immunity (NCI: Checkpoint Inhibitors, 2024). Therapeutic strategies also include the adoptive transfer of these cells, often genetically modified with Chimeric Antigen Receptors (CARs), to provide targeted destruction of cancer cells (Nature Reviews Clinical Oncology, 2023).

Other names
CD8+ T-lymphocyteKiller T-cellNK cellLarge granular lymphocyteCytotoxic effector cell
02

Mechanism of action

Drugs modulate these cells by blocking inhibitory checkpoints (e.g., PD-1, CTLA-4), providing stimulatory cytokines (e.g., IL-2), or using them as effectors for antibody-dependent cellular cytotoxicity (ADCC) (Nature Reviews Immunology, 2020; NCI, 2024).

03

Biological functions

Immune responseApoptosisCell deathCytokine productionCellular cytotoxicity
04

Disease associations

CancerInfectionOther (Autoimmune disease)Other (Graft-versus-host disease)
05

Safety considerations

Cytokine release syndrome (CRS)Immune-related adverse events (irAEs)On-target off-tumor toxicityNeurotoxicity (ICANS)Graft-versus-host disease (GvHD)
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

CD8 (CTL marker)CD56 (NK marker)CD16 (NK marker/Fc receptor)Granzyme B (GZMB)Perforin (PRF1)Interferon-gamma (IFNG)NKG2DPD-1 expression

Beyond the preview

Go deeper on Cytotoxic T-lymphocyte (CTL) and Natural killer (NK) cell (CTL/NK cell).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytotoxic T-lymphocyte (CTL) and Natural killer (NK) cell (CTL/NK cell).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call